Historical Valuation
Quest Diagnostics Inc (DGX) is now in the Fair zone, suggesting that its current forward PE ratio of 17.04 is considered Fairly compared with the five-year average of 15.64. The fair price of Quest Diagnostics Inc (DGX) is between 161.40 to 193.74 according to relative valuation methord.
Relative Value
Fair Zone
161.40-193.74
Current Price：174.44
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Quest Diagnostics Inc (DGX) has a current Price-to-Book (P/B) ratio of 2.66. Compared to its 3-year average P/B ratio of 2.55 , the current P/B ratio is approximately 4.16% higher. Relative to its 5-year average P/B ratio of 2.59, the current P/B ratio is about 2.79% higher. Quest Diagnostics Inc (DGX) has a Forward Free Cash Flow (FCF) yield of approximately 7.21%. Compared to its 3-year average FCF yield of 5.86%, the current FCF yield is approximately 22.93% lower. Relative to its 5-year average FCF yield of 7.76% , the current FCF yield is about -7.16% lower.
P/B
Median3y
2.55
Median5y
2.59
FCF Yield
Median3y
5.86
Median5y
7.76
Competitors Valuation Multiple
AI Analysis for DGX
The average P/S ratio for DGX competitors is 1.43, providing a benchmark for relative valuation. Quest Diagnostics Inc Corp (DGX.N) exhibits a P/S ratio of 1.71, which is 20.02% above the industry average. Given its robust revenue growth of 13.18%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for DGX
1Y
3Y
5Y
Market capitalization of DGX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of DGX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is DGX currently overvalued or undervalued?
Quest Diagnostics Inc (DGX) is now in the Fair zone, suggesting that its current forward PE ratio of 17.04 is considered Fairly compared with the five-year average of 15.64. The fair price of Quest Diagnostics Inc (DGX) is between 161.40 to 193.74 according to relative valuation methord.
What is Quest Diagnostics Inc (DGX) fair value?
DGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Quest Diagnostics Inc (DGX) is between 161.40 to 193.74 according to relative valuation methord.
How does DGX's valuation metrics compare to the industry average?
The average P/S ratio for DGX's competitors is 1.43, providing a benchmark for relative valuation. Quest Diagnostics Inc Corp (DGX) exhibits a P/S ratio of 1.71, which is 20.02% above the industry average. Given its robust revenue growth of 13.18%, this premium appears unsustainable.
What is the current P/B ratio for Quest Diagnostics Inc (DGX) as of Jan 10 2026?
As of Jan 10 2026, Quest Diagnostics Inc (DGX) has a P/B ratio of 2.66. This indicates that the market values DGX at 2.66 times its book value.
What is the current FCF Yield for Quest Diagnostics Inc (DGX) as of Jan 10 2026?
As of Jan 10 2026, Quest Diagnostics Inc (DGX) has a FCF Yield of 7.21%. This means that for every dollar of Quest Diagnostics Inc’s market capitalization, the company generates 7.21 cents in free cash flow.
What is the current Forward P/E ratio for Quest Diagnostics Inc (DGX) as of Jan 10 2026?
As of Jan 10 2026, Quest Diagnostics Inc (DGX) has a Forward P/E ratio of 17.04. This means the market is willing to pay $17.04 for every dollar of Quest Diagnostics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Quest Diagnostics Inc (DGX) as of Jan 10 2026?
As of Jan 10 2026, Quest Diagnostics Inc (DGX) has a Forward P/S ratio of 1.71. This means the market is valuing DGX at $1.71 for every dollar of expected revenue over the next 12 months.